145 related articles for article (PubMed ID: 38392199)
1. Targeted Sequencing in Gastric Cancer: Association with Tumor Molecular Characteristics and FLOT Therapy Effectiveness.
Spirina LV; Avgustinovich AV; Bakina OV; Afanas'ev SG; Volkov MY; Vtorushin SV; Kovaleva IV; Klyushina TS; Munkuev IO
Curr Issues Mol Biol; 2024 Feb; 46(2):1281-1290. PubMed ID: 38392199
[TBL] [Abstract][Full Text] [Related]
2. The genomic and immune landscapes of gastric cancer and their correlations with HER2 amplification and PD-L1 expression.
Jing X; Luo Z; Wu J; Ye F; Li J; Song Z; Zhang Y; Shi M; Sun H; Fang Y; Jiang Y; Ji X
Cancer Med; 2023 Dec; 12(24):21905-21919. PubMed ID: 38050871
[TBL] [Abstract][Full Text] [Related]
3. Low PTEN levels and PIK3CA mutations predict resistance to neoadjuvant lapatinib and trastuzumab without chemotherapy in patients with HER2 over-expressing breast cancer.
Rimawi MF; De Angelis C; Contreras A; Pareja F; Geyer FC; Burke KA; Herrera S; Wang T; Mayer IA; Forero A; Nanda R; Goetz MP; Chang JC; Krop IE; Wolff AC; Pavlick AC; Fuqua SAW; Gutierrez C; Hilsenbeck SG; Li MM; Weigelt B; Reis-Filho JS; Kent Osborne C; Schiff R
Breast Cancer Res Treat; 2018 Feb; 167(3):731-740. PubMed ID: 29110152
[TBL] [Abstract][Full Text] [Related]
4. Expression Profile of Markers for Targeted Therapy in Gastric Cancer Patients: HER-2, Microsatellite Instability and PD-L1.
Pereira MA; Ramos MFKP; Dias AR; Faraj SF; Ribeiro RRE; de Castria TB; Zilberstein B; Alves VAF; Ribeiro U; de Mello ES
Mol Diagn Ther; 2019 Dec; 23(6):761-771. PubMed ID: 31595457
[TBL] [Abstract][Full Text] [Related]
5. Integration of comprehensive genomic profiling, tumor mutational burden, and PD-L1 expression to identify novel biomarkers of immunotherapy in non-small cell lung cancer.
Shi Y; Lei Y; Liu L; Zhang S; Wang W; Zhao J; Zhao S; Dong X; Yao M; Wang K; Zhou Q
Cancer Med; 2021 Apr; 10(7):2216-2231. PubMed ID: 33655698
[TBL] [Abstract][Full Text] [Related]
6. Safety and Efficacy of Neoadjuvant Chemoimmunotherapy in Gastric Cancer Patients with a PD-L1 Positive Status: A Case Report.
Avgustinovich AV; Bakina OV; Afanas'ev SG; Spirina LV; Volkov AM
Curr Issues Mol Biol; 2023 Sep; 45(9):7642-7649. PubMed ID: 37754265
[TBL] [Abstract][Full Text] [Related]
7. Somatic mutations in a multigene panel and impact on prognosis based on TP53 status in Chinese HER2-positive patients undergoing neoadjuvant therapy: A single-institution retrospective cohort.
Xiong M; Wang X; Liu D; Xiu B; Zhang Q; Chi W; Goh CW; Zhang L; Chen M; Ren H; Shao ZM; Yang B; Wu J
Cancer Med; 2024 Jan; 13(2):e6955. PubMed ID: 38379328
[TBL] [Abstract][Full Text] [Related]
8. Impact of somatic PI3K pathway and ERBB family mutations on pathological complete response (pCR) in HER2-positive breast cancer patients who received neoadjuvant HER2-targeted therapies.
Toomey S; Eustace AJ; Fay J; Sheehan KM; Carr A; Milewska M; Madden SF; Teiserskiene A; Kay EW; O'Donovan N; Gallagher W; Grogan L; Breathnach O; Walshe J; Kelly C; Moulton B; Kennedy MJ; Gullo G; Hill AD; Power C; Duke D; Hambly N; Crown J; Hennessy BT
Breast Cancer Res; 2017 Jul; 19(1):87. PubMed ID: 28750640
[TBL] [Abstract][Full Text] [Related]
9. PD-L1 Status in Gastric Cancers, Association with the Transcriptional, Growth Factors, AKT/mTOR Components Change, and Autophagy Initiation.
Spirina L; Avgustinovich A; Afanas'ev S; Volkov M; Dobrodeev A; Cheremisina O; Kostromitsky D
Int J Mol Sci; 2021 Oct; 22(20):. PubMed ID: 34681840
[TBL] [Abstract][Full Text] [Related]
10. Molecular diagnostic characteristics based on the next generation sequencing in lung cancer and its relationship with the expression of PD-L1.
Liu J; Liu Y
Pathol Res Pract; 2020 Feb; 216(2):152797. PubMed ID: 31926773
[TBL] [Abstract][Full Text] [Related]
11. Genetic mutation profile of Chinese HER2-positive breast cancers and genetic predictors of responses to Neoadjuvant anti-HER2 therapy.
Li K; Liao N; Chen B; Zhang G; Wang Y; Guo L; Wei G; Jia M; Wen L; Ren C; Cao L; Mok H; Li C; Lin J; Chen X; Zhang Z; Hou T; Li M; Liu J; Balch CM; Liao N
Breast Cancer Res Treat; 2020 Sep; 183(2):321-332. PubMed ID: 32638235
[TBL] [Abstract][Full Text] [Related]
12. Prevalence and spectrum of AKT1, PIK3CA, PTEN and TP53 somatic mutations in Chinese breast cancer patients.
Li G; Guo X; Chen M; Tang L; Jiang H; Day JX; Xie Y; Peng L; Xu X; Li J; Wang S; Xiao Z; Dai L; Wang J
PLoS One; 2018; 13(9):e0203495. PubMed ID: 30212483
[TBL] [Abstract][Full Text] [Related]
13. Clinicopathological features of tumor mutation burden, Epstein-Barr virus infection, microsatellite instability and PD-L1 status in Chinese patients with gastric cancer.
Zhang L; Wang Y; Li Z; Lin D; Liu Y; Zhou L; Wang D; Wu A; Li Z
Diagn Pathol; 2021 May; 16(1):38. PubMed ID: 33933102
[TBL] [Abstract][Full Text] [Related]
14. High-throughput interrogation of PIK3CA, PTEN, KRAS, FBXW7 and TP53 mutations in primary endometrial carcinoma.
Garcia-Dios DA; Lambrechts D; Coenegrachts L; Vandenput I; Capoen A; Webb PM; Ferguson K; ; Akslen LA; Claes B; Vergote I; Moerman P; Van Robays J; Marcickiewicz J; Salvesen HB; Spurdle AB; Amant F
Gynecol Oncol; 2013 Feb; 128(2):327-34. PubMed ID: 23219661
[TBL] [Abstract][Full Text] [Related]
15. Deep Targeted Sequencing and Its Potential Implication for Cancer Therapy in Chinese Patients with Gastric Adenocarcinoma.
Yu P; Wang Y; Yu Y; Wang A; Huang L; Zhang Y; Liu W; Wu H; Yao M; Du YA; Cheng X
Oncologist; 2021 May; 26(5):e756-e768. PubMed ID: 33511732
[TBL] [Abstract][Full Text] [Related]
16. Identification of molecular features correlating with tumor immunity in gastric cancer by multi-omics data analysis.
He Y; Wang X
Ann Transl Med; 2020 Sep; 8(17):1050. PubMed ID: 33145269
[TBL] [Abstract][Full Text] [Related]
17. PIK3CA somatic mutations as potential biomarker for immunotherapy in elder or TP53 mutated gastric cancer patients.
Yao J; You Q; Zhang X; Zhang Y; Xu J; Zhao X; Li J; Wang X; Gong Z; Zhang D; Wang W
Clin Genet; 2023 Feb; 103(2):200-208. PubMed ID: 36346122
[TBL] [Abstract][Full Text] [Related]
18. Comparison of mutational profiles between triple-negative and hormone receptor-positive/human epidermal growth factor receptor 2-negative breast cancers in T2N0-1M0 stage: Implications of TP53 and PIK3CA mutations in Korean early-stage breast cancers.
Lee S; Kim HY; Jung YJ; Jung CS; Im D; Kim JY; Lee SM; Oh SH
Curr Probl Cancer; 2022 Apr; 46(2):100843. PubMed ID: 35180531
[TBL] [Abstract][Full Text] [Related]
19. Immune microenvironment features and efficacy of PD-1/PD-L1 blockade in non-small cell lung cancer patients with EGFR or HER2 exon 20 insertions.
Chen K; Pan G; Cheng G; Zhang F; Xu Y; Huang Z; Fan Y
Thorac Cancer; 2021 Jan; 12(2):218-226. PubMed ID: 33210451
[TBL] [Abstract][Full Text] [Related]
20. Cure Is Possible: Extensively Metastatic HER2-Positive Gastric Carcinoma with 5 years of Complete Remission after Therapy with the FLOT Regimen and Trastuzumab.
Schade S; Koenig U; Mekolli A; Gaedcke J; Neesse A; Reinecke J; Brunner M; Amir Hosseini AS; Kitz J; Stroebel P; Lotz J; Ghadimi M; Ellenrieder V; Koenig A
Case Rep Gastroenterol; 2022; 16(1):80-88. PubMed ID: 35350679
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
